An Ex-Vivo Pharmacodynamic Study Comparing Bactericidal Activity of Amoxicillin/Sulbactam, Azithromycin, Doxycycline and Levofloxacin Against Streptococcus pneumoniae

REFERENCES

• Bantar C, Bavestrello L, Curcio D et al. Acute commu-nity-acquired pneumonia in adults: guidelines for initial antimi-crobial therapy based on local evidence from a South American Working Group (ConsenSur). J Chemother 2002; 14 (Suppl 4): 1–22.
   Google Scholar
• Bartlett JG, Dowell SF, Mandell LA et al. Practice guidelines for the management of community-acquired pneu-monia in adults. Clin Infect Dis 2000; 31: 347–382.
   PubMedGoogle Scholar
• Mandell LA, Marrie TJ, Grossman RF et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000; 31: 383–421.
   Google Scholar
• Huchon G; European Study on Community-Acquired Pneumonia. Guidelines for management of adult community-acquired lower respiratory tract infections. Eur Resp J 1998; 11: 986–991.
   Google Scholar
• Niederman MS, Mandell LA, Anzueto A et al. Guidelines for management of adults with community-acquired pneumonia. Am J Resp Clin Care Med 2001; 163: 1730–1754.
   PubMed Web of Science ®Google Scholar
• BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 2001; 56 (Suppl 4): ivl-iv64.
   Google Scholar
• Kelley MA, Weber DJ, Gilligan P et al. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31: 1008–1011.
   Google Scholar
• Lisby G, Brasholt MS, Teglbjerg M. Bacteremia and meningitis caused by a macrolide-sensitive strain of Streptococcus pneumoniae during treatment with azithromycin. Clin Infect Dis 2001; 33: 415–416.
   PubMed Web of Science ®Google Scholar
• Lonks JR, Garau J, Gomez L et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to ery-thromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2000; 35: 556–564.
   Google Scholar
• Davidson R, Cavalcanti R, Brunton JL et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. New Eng J Med 2002; 346: 747–750.
   Google Scholar
• Ross JJ, Worthington MG, Gorbach SL. Resistance to levofloxacin and failure of treatment of pneumococcal pneu-monia [letter]. New Eng J Med 2002; 347: 65–66.
   PubMed Web of Science ®Google Scholar
• Bishai W. The in vivo-in vitro paradox in pneumococcal respiratory tract infection. J Antimicrob Chemother 2002; 49: 433–436.
   PubMed Web of Science ®Google Scholar
• Bantar C, Nicola F, Fernandez Canigia L et al. A phar-macodynamic model to support a twelve-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections. J Chemother 2000; 12: 223–227.
   Google Scholar
• Jasovich A, Soutric J, Morera G et al. Efficacy of amoxicillin-sulbactam, given twice-a-day, for the treatment of community- acquired pneumonia. A clinical trial based on a pharmacodynamic model. J Chemother 2002; 14: 591–596.
   Google Scholar
• National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility test for bacte-ria that grow aerobically. Approved standard M7-A5. 2000. National Committee for Clinical Laboratory Standards, Villanova, Pa.
   Google Scholar
• den Hollander JG, Knudsen JD, Mouton WJ et al. Comparison of pharmacodynamics of azithromycin and ery-thromycin in vitro and in vivo. Antimicrob Agents Chemother 1998; 42: 377–382.
   Google Scholar
• Ruhen RW, Tandon MK. Minocycline, doxycycline and tetracycline levels in serum and bronchial secretions of patients with chronic bronchitis. Pathology 1975; 7: 193–197
   PubMed Web of Science ®Google Scholar
• Sakellari D, Goodson JM, Kolokotronis A et al. Concentration of 3 tetracyclines in plasma, gingival crevice fluid and saliva. J Clin Periodontol 2000; 27: 53–60
   Google Scholar
• Berry V, Thorburn CE, Knott SJ, et al. Bacteriological efficacies of three macrolides compared with those of amoxi-cillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob Agents Chemother 1998; 42: 3193–3199.
   PubMed Web of Science ®Google Scholar
• Musher DM, Dowell ME, Shortridge VD et al. Emergence of macrolide resistance during treatment of pneu-mococcal pneumonia [letter]. N Engl J Med 2002; 346: 630–631.
   PubMed Web of Science ®Google Scholar
• Joshi N, Miller DO. Doxycycline revisited. Arch Intern Med 1997; 157: 1421–1428.
   PubMedGoogle Scholar
• Tice AD. Doxycycline: new ways to use an old antibiotic [letter]. Arch Intern Med 1998; 158: 928–929.
   PubMedGoogle Scholar
• Ailani RK, Agastya G, Ailani RK et al. Doxycycline is a cost-effective therapy for hospitalized patients with communi-ty- acquired pneumonia. Arch Intern Med 1999; 159: 266–270.
   Google Scholar
• Ditmanson L, Apgar D, Tuscon A. Treatment for com-munity acquired pneumonia: more support for doxycycline [letter]. Arch Intern Med 1999; 159: 1814–1815.
   PubMedGoogle Scholar
• Shah PM. Serum bactericidal activity of levofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 1999; 43 (Suppl. C): 61-65.
   Google Scholar
• Lister PD, Sanders CC. Pharmacodynamics of lev-ofloxacin and ciprofloxacin against Streptococcus pneumoni-ae. J Antimicrob Chemother 1999; 43: 79–86.
   PubMed Web of Science ®Google Scholar
• Ho PL, Tse WS, Tsang KW et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoni-ae: a case-control study. Clin Infect Dis 2001; 32: 701–707.
   Google Scholar
• Craig WA. Pharmacokinetic/pharmacodynamic para-meter: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1997; 26: 1–12.
   Web of Science ®Google Scholar
• Calver A, Walsh N, Quinn P et al. Dosing of amoxi-cillin/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infec-tion. Clin Infect Dis 1997; 24: 570–574.
   Google Scholar
• Masson JM, Kazmierczak A, Labia R. Interactions of clavulanic acid and sulbactam with penicilin-binding proteins. Drugs Exp Clin Res 1983; 9: 513–518.
   Google Scholar
• Carsenti-Etesse H, Duran J, De Salvador F, et al. Possible prevention of in vitro selection of resistant Streptococcus pneumoniae by beta-lactamase inhibitors. Eur J Clin Microbiol Infect Dis 1994; 13: 1058–1062.
   PubMed Web of Science ®Google Scholar